经肛全直肠系膜切除治疗直肠癌十年回顾与展望

doi:10.3969/j.issn.2095-378X.2023.01.001

摘要/Abstract

摘要： 直肠癌是消化道最常见的恶性肿瘤之一。以手术为中心的多学科疗法仍是治疗直肠癌的主要策略。在我国,直肠癌以中低位居多,近年来,经肛全直肠系膜切除（taTME）成为中低位直肠癌手术的热点领域。自2010年首次报道至今,taTME手术已历经逾10年的发展,该术式在技术上的不断进步,已逐渐形成了一套较为规范的理论和实践体系。同时,国内外研究的持续推进以及专家共识和指南的迭代推出,为该术式的安全性与有效性提供了科学证据。未来,期待我国的研究中心开展更广泛的结构化培训和临床试验,获得基于我国taTME临床研究结果的高级别循证医学证据,形成更成熟的的taTME临床实践指南,来更安全规范地开展该技术,以期望为更多的直肠癌患者带来获益。

关键词: 直肠癌, 经肛全直肠系膜切除, 结构化培训, 临床研究

Abstract: Rectal cancer is one of the most common malignant tumors of the gastrointestinal tract. Surgery-centered multidisciplinary therapy is still the main strategy for the treatment of rectal cancer. In China, low-to-mid rectal cancer accounts for the majority. In recent years, transanal total mesorectal excision (taTME) has become a hot area of surgery for low-to-mid rectal cancer. Since it was first reported in 2010, taTME has undergone about 10 years of development, and a standardized theoretical and practical system has been gradually formed as a result of the continuous technical progress of this procedure. Meanwhile, the continuous advancement of domestic and international research and the iterative launch of expert consensus and guidelines have provided scientific evidence for the safety and efficacy of this procedure. In the future, it is expected that research centers in China will carry out more extensive structured training and clinical trials to obtain high-level evidence-based clinical research results of taTME, and form more mature clinical practice guidelines to carry out this technique in a safer and more standardized manner, in the hope of bringing benefits to more rectal cancer patients.

Key words: Rectal cancer, Transanal total mesorectal excision, Structured training, Clinical research

中图分类号:

R735.3⁺7

魏鹏宇, 李杨, 高加勒, 姚宏伟, 张忠涛. 经肛全直肠系膜切除治疗直肠癌十年回顾与展望[J]. 外科研究与新技术, 2023, 12(1): 1-5.

WEI Pengyu, LI Yang, GAO Jiale, YAO Hongwei, ZHANG Zhongtao. Ten-year review and prospect of transanal total mesorectal excision for rectal cancer[J]. Surgical Research and New Technique, 2023, 12(1): 1-5.

参考文献

[1] Siegel RL, Miller K D, Fuchs H E, et al.Cancer statistics, 2022[J]. CA Cancer J Clin, 2022, 72(1): 7-33.
[2] Zheng R, Zhang S, Zeng H, et al.Cancer incidence and mortality in China, 2016[J]. J Nat Cancer Cent, 2022, 2(1): 1-9.
[3] 姚宏伟, 李心翔, 崔龙, 等. 中国结直肠癌手术病例登记数据库2019年度报告:一项全国性登记研究[J]. 中国实用外科杂志, 2020, 40(1): 106-110.
[4] Sylla P, Rattner DW, Delgado S, et al.NOTES transanal rectal cancer resection using transanal endoscopic microsurgery and laparoscopic assistance[J]. Surg Endosc, 2010, 24(5): 1205-1210.
[5] Heald RJ, Husband EM, Ryall RD.The mesorectum in rectal cancer surgery—the clue to pelvic recurrence [J]. Br J Surg, 1982, 69(10): 613-616.
[6] Jacobs M, Verdeja JC, Goldstein HS.Minimally invasive colon resection (laparoscopic colectomy)[J]. Surg Laparosc Endosc, 1991, 1(3): 144-150.
[7] Guillou PJ, Quirke P, Thorpe H, et al.Short-term endpoints of conventional versus laparoscopic-assisted surgery in patients with colorectal cancer (MRC CLASICC trial): multicentre, randomised controlled trial[J]. Lancet, 2005, 365(9472): 1718-1726.
[8] Kang SB, Park JW, Jeong SY, et al.Open versus laparoscopic surgery for mid or low rectal cancer after neoadjuvant chemoradiotherapy (COREAN trial): short-term outcomes of an open-label randomised controlled trial[J]. Lancet Oncol, 2010, 11(7): 637-645.
[9] Bonjer HJ, Deijen CL, Abis GA, et al.A randomized trial of laparoscopic versus open surgery for rectal cancer[J]. N Engl J Med, 2015, 372(14): 1324-1332.
[10] Jiang WZ, Xu JM, Xing JD, et al.Short-term outcomes of laparoscopy-assisted vs open surgery for patients with low rectal cancer: the LASRE randomized clinical trial[J]. JAMA Oncol, 2022, 8(11): 1607-1615.
[11] Fleshman J, Branda M, Sargent DJ, et al.Effect of laparoscopic-assisted resection vs open resection of stage Ⅱ or Ⅲ rectal cancer on pathologic outcomes: the ACOSOG Z6051 randomized clinical trial[J]. JAMA, 2015, 314(13): 1346-1355.
[12] Stevenson A R, Solomon M J, Lumley J W, et al.Effect of laparoscopic-assisted resection vs open resection on pathological outcomes in rectal cancer: the ALaCaRT randomized clinical trial[J]. JAMA, 2015, 314(13): 1356-1363.
[13] 陈远光, 胡明, 雷建, 等. 经肛内镜全直肠系膜切除治疗直肠癌[J]. 中国内镜杂志, 2010, 16(12): 1261-1265.
[14] 张浩, 张云生, 金雄伟, 等. 完全经肛单孔腹腔镜全直肠系膜切除术治疗直肠癌[J]. 中国内镜杂志, 2012, 18(4): 379-383.
[15] Zhang H, Zhang YS, Jin XW, et al.Transanal single-port laparoscopic total mesorectal excision in the treatment of rectal cancer[J]. Tech Coloproctol, 2013, 17(1): 117-123.
[16] TaTME Guidance Group representing the ESCP (European Society of Coloproctology), in collaboration with the ASCRS (American Society of Colon and Rectal Surgeons), ACPGBI (Association of Coloproctology of Great Britain and Ireland), ECCO (European Crohn’s and Colitis Organisation), EAES (European Association of Endoscopic Surgeons), ESSO (European Society of Surgical Oncology), CSCRS (Canadian Society of Colorectal Surgery), CNSCRS (Chinese Society of Colorectal Surgery), CSLES (Chinese Society of Laparo-Endoscopic Surgery), CSSANZ (Colorectal Surgical Society of Australia and New Zealand), JSES (Japanese Society of Endoscopic Surgery), SACP (Argentinian Society of Coloproctology), SAGES (Society of American Gastrointestinal and Endoscopic Surgeons), BSCP (Brazilian Society of Coloproctology), Swiss-MIS (Swiss Association for Minimally Invasive Surgery). International expert consensus guidance on indications, implementation and quality measures for transanal total mesorectal excision[J]. Colorectal Dis, 2020, 22(7): 749-755.
[17] Adamina M, Buchs NC, Penna M, et al.St.Gallen consensus on safe implementation of transanal total mesorectal excision[J]. Surg Endosc, 2018, 32(3): 1091-1103.
[18] 张忠涛, 郑民华, 姚宏伟, 等. 直肠癌经肛全直肠系膜切除专家共识及手术操作指南(2017版)[J]. 中国实用外科杂志, 2017, 37(9): 978-984.
[19] 姚宏伟, 张忠涛, 郑民华. 直肠癌经肛全直肠系膜切除中国专家共识及临床实践指南(2019版)[J]. 中国实用外科杂志, 2019, 39(11): 1121-1128.
[20] 姚宏伟, 陈建志, 张宏宇, 等. 中国经肛全直肠系膜切除手术病例登记协作研究数据库2018年度报告:一项全国性登记研究[J]. 中国实用外科杂志, 2019, 39(1): 85-91.
[21] Penna M, Hompes R, Arnold S, et al.Transanal total mesorectal excision: International registry results of the first 720 cases[J]. Ann Surg, 2017, 266(1): 111-117.
[22] Marks JH, Myers EA, Zeger EL, et al.Long-term outcomes by a transanal approach to total mesorectal excision for rectal cancer[J]. Surg Endosc, 2017, 31(12): 5248-5257.
[23] Yao H, An Y, Zhang H, et al.Transanal total mesorectal excision: short-term outcomes of 1283 cases from a nationwide registry in China[J]. Dis Colon Rectum, 2021, 64(2): 190-199.
[24] Larsen SG, Pfeffer F, Korner H, et al.Norwegian moratorium on transanal total mesorectal excision[J]. Br J Surg, 2019, 106(9): 1120-1121.
[25] Deijen CL, Velthuis S, Tsai A, et al.COLOR Ⅲ: a multicentre randomised clinical trial comparing transanal TME versus laparoscopic TME for mid and low rectal cancer[J]. Surg Endosc, 2016, 30(8): 3210-3215.
[26] Lelong B, DE Chaisemartin C, Meillat H, et al.A multicentre randomised controlled trial to evaluate the efficacy, morbidity and functional outcome of endoscopic transanal proctectomy versus laparoscopic proctectomy for low-lying rectal cancer (ETAP-GRECCAR 11 TRIAL): rationale and design[J]. BMC Cancer, 2017, 17(1): 253.